Breaking News Instant updates and real-time market news.

PFPT

Proofpoint

$117.13

5.14 (4.59%)

12:55
08/21/19
08/21
12:55
08/21/19
12:55

Proofpoint participates in a conference call with Wedbush

Software Analyst Koenig holds a conference call with CFO Auvil and EVP Knight on August 21 at 1:30 pm hosted by Wedbush.

  • 21

    Aug

  • 28

    Aug

  • 28

    Aug

  • 05

    Sep

  • 10

    Oct

  • 15

    Oct

  • 13

    Nov

  • 12

    Dec

  • 16

    Dec

PFPT Proofpoint
$117.13

5.14 (4.59%)

07/26/19
PIPR
07/26/19
NO CHANGE
Target $145
PIPR
Overweight
Proofpoint price target raised to $145 from $140 at Piper Jaffray
Piper Jaffray analyst Andrew Nowinski raised his price target for Proofpoint (PFPT) to $145 from $140 saying the company's Q2 results were "very consistent with historical standards," beating the high-end of revenue guidance by 1.2% and billings by 0.9%.Management only raised the annual guidance by roughly the same amount as the beat, likely setting up for another beat in Q3, Nowinski tells investors in a research note. He believes Proofpoint continues to extend its lead in terms of market share over Microsoft (MSFT) and others, and reiterates an Overweight rating on the shares.
07/26/19
NEED
07/26/19
NO CHANGE
Target $150
NEED
Buy
Proofpoint price target raised to $150 from $135 at Needham
Needham analyst Alex Henderson raised his price target on Proofpoint to $150 and kept his Buy rating after its beat-and-raise Q2 results, with "strong" operating leverage and "excellent" free cash flows driving the company's longer-term targets ahead of schedule. The analyst adds that Proofpoint's international opportunity is a "key part" of his investment thesis, with revenues growing 33% in the most recent quarter but still accounting for just 19% of the total.
07/29/19
JMPS
07/29/19
NO CHANGE
Target $140
JMPS
Outperform
Proofpoint price target raised to $140 from $130 at JMP Securities
JMP Securities analyst Erik Suppiger raised his price target on Proofpoint shares to $140 from $130 after the company reported better than expected Q2 results and guided billings, revenue and EPS above consensus for the next quarter. The analyst, who previously projected a decline in gross margins, noted that their advance exceeded his expectations, said that Proofpoint's emerging products continue to perform well, and that the company's Wombat phishing training product is gaining "significant momentum." Suppiger keeps an Outperform rating on Proofpoint shares.
08/13/19
BOFA
08/13/19
NO CHANGE
Target $103
BOFA
Buy
Crowdstrike price target raised to $103 from $89 at BofA/Merrill
BofA Merrill Lynch analyst Tal Liani noted that he had expected and incorporated some share gains for Crowdstrike (CRWD) from Symantec (SYMC) in his model, but following the recent announcement that Broadcom (AVGO) intends to buy Symantec's enterprise business he sees the potential for those share gains to accelerate. Liani, who raised his price target on Crowdstrike shares to $103 from $89, reiterated a Buy rating on the stock. Aside from the potential for Crowdstrike in antivirus, Liani sees other areas of cyber security where Symantec leads and he could see shares losses should Broadcom's deal create any uncertainty around Symantec's roadmap or commitment to R&D in the space. In email security the beneficiaries would be Proofpoint (PFPT) and Mimecast (MIME) and in secure web gateways the beneficiary could be Zscaler (ZS), Liani noted.

TODAY'S FREE FLY STORIES

TSM

TSMC

$45.15

0.55 (1.23%)

, AMD

AMD

$31.00

0.17 (0.55%)

07:51
09/18/19
09/18
07:51
09/18/19
07:51
Periodicals
TSMC extends production lead time for 7nm chip capacity, DIgiTimes reports »

TSMC (TSM) is extending…

TSM

TSMC

$45.15

0.55 (1.23%)

AMD

AMD

$31.00

0.17 (0.55%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

CBRL

Cracker Barrel

$167.79

2.84 (1.72%)

07:50
09/18/19
09/18
07:50
09/18/19
07:50
Recommendations
Cracker Barrel analyst commentary  »

Cracker Barrel price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:50
09/18/19
09/18
07:50
09/18/19
07:50
General news
U.S. MBA reported mortgage applications dipped -0.1% in the September 13 week »

U.S. MBA reported…

AKTS

Akoustis

$7.90

0.1 (1.28%)

07:48
09/18/19
09/18
07:48
09/18/19
07:48
Downgrade
Akoustis rating change  »

Northland downgrades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

  • 12

    Nov

ACHV

Achieve Life Sciences

$2.23

-0.03 (-1.33%)

07:46
09/18/19
09/18
07:46
09/18/19
07:46
Conference/Events
Achieve Life Sciences to host investor day »

Investor day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 24

    Sep

CBWTF

Auxly Cannabis

$0.00

(0.00%)

07:45
09/18/19
09/18
07:45
09/18/19
07:45
Hot Stocks
Auxly Cannabis announces Canadian brokerage agreement with Kindred Partners »

Auxly Cannabis Group and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IOTS

Adesto Technologies

$10.63

-0.66 (-5.85%)

07:45
09/18/19
09/18
07:45
09/18/19
07:45
Initiation
Adesto Technologies initiated  »

Adesto Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ONCE

Spark Therapeutics

$104.41

-0.41 (-0.39%)

07:43
09/18/19
09/18
07:43
09/18/19
07:43
Hot Stocks
Spark Therapeutics, paralympic skier partner for genetic testing awareness »

Spark Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KLAC

KLA-Tencor

$152.55

1.38 (0.91%)

07:42
09/18/19
09/18
07:42
09/18/19
07:42
Recommendations
KLA-Tencor analyst commentary  »

KLA-Tencor price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VTVT

vTv Therapeutics

$1.73

-0.045 (-2.54%)

07:40
09/18/19
09/18
07:40
09/18/19
07:40
Hot Stocks
vTv Therapeutics presents additional data from Phase 2 Simplici-T1 study »

vTv Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Oct

07:40
09/18/19
09/18
07:40
09/18/19
07:40
General news
Treasury Market Outlook: yields extended declines overnight »

Treasury Market Outlook:…

GSK

GlaxoSmithKline

$41.10

0.49 (1.21%)

07:38
09/18/19
09/18
07:38
09/18/19
07:38
Conference/Events
FDA Non-Prescription Drugs Advisory Committee to hold a meeting »

The Committee discusses…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

  • 24

    Sep

  • 27

    Sep

  • 02

    Oct

OPGN

OpGen

$7.02

-0.07 (-0.99%)

07:37
09/18/19
09/18
07:37
09/18/19
07:37
Hot Stocks
OpGen says Curetis collaborator obtains option to license ARESdb »

OpGen reported an update…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLK

BlackRock

$438.98

3.12 (0.72%)

, TROW

T. Rowe Price

$117.98

1.1 (0.94%)

07:37
09/18/19
09/18
07:37
09/18/19
07:37
Recommendations
BlackRock, T. Rowe Price analyst commentary  »

BlackRock's…

BLK

BlackRock

$438.98

3.12 (0.72%)

TROW

T. Rowe Price

$117.98

1.1 (0.94%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 26

    Sep

  • 27

    Oct

AXDX

Accelerate Diagnostics

$21.30

1.85 (9.51%)

07:36
09/18/19
09/18
07:36
09/18/19
07:36
Hot Stocks
Accelerate Diagnostics reports 'positive' results in three Pheno system studies »

Accelerate Diagnostics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

ADBE

Adobe

$284.59

1.54 (0.54%)

, WWE

WWE

$75.88

1.73 (2.33%)

07:35
09/18/19
09/18
07:35
09/18/19
07:35
Options
Unusual call flow in option market yesterday »

Notable call activity was…

ADBE

Adobe

$284.59

1.54 (0.54%)

WWE

WWE

$75.88

1.73 (2.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 27

    Oct

BIIB

Biogen

$238.65

2.54 (1.08%)

07:34
09/18/19
09/18
07:34
09/18/19
07:34
Hot Stocks
Biogen to present new data from SHINE study on safety and efficacy of SPINRAZA »

Biogen announced updates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

IAC

IAC

$236.73

7.5 (3.27%)

, MTCH

Match Group

$79.70

3 (3.91%)

07:33
09/18/19
09/18
07:33
09/18/19
07:33
Recommendations
IAC, Match Group, Angi Homeservices analyst commentary  »

IAC spinoffs could unlock…

IAC

IAC

$236.73

7.5 (3.27%)

MTCH

Match Group

$79.70

3 (3.91%)

ANGI

Angi Homeservices

$7.60

-0.31 (-3.92%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Oct

EFX

Equifax

$141.79

1.78 (1.27%)

07:32
09/18/19
09/18
07:32
09/18/19
07:32
Hot Stocks
Equifax partners with Urjanet for utility payment data sharing platform »

Equifax and Urjanet…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

  • 13

    Nov

BHVN

Biohaven Pharmaceutical

$47.24

-0.8 (-1.67%)

07:32
09/18/19
09/18
07:32
09/18/19
07:32
Hot Stocks
Biohaven Pharmaceutical's verdiperstat selected for ALS platform trial »

Biohaven Pharmaceutical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BIIB

Biogen

$238.65

2.54 (1.08%)

07:32
09/18/19
09/18
07:32
09/18/19
07:32
Hot Stocks
Biogen to initiate DEVOTE clinical trial evaluating higher dose of SPINRAZA »

Biogen announced updates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

FDX

FedEx

$173.53

-0.14 (-0.08%)

, UPS

UPS

$122.40

-0.245 (-0.20%)

07:30
09/18/19
09/18
07:30
09/18/19
07:30
Recommendations
FedEx, UPS analyst commentary  »

Hard to see rebound for…

FDX

FedEx

$173.53

-0.14 (-0.08%)

UPS

UPS

$122.40

-0.245 (-0.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

  • 19

    Sep

  • 23

    Sep

  • 30

    Sep

  • 01

    Oct

  • 13

    Nov

  • 17

    Dec

MAS

Masco

$41.28

-1.44 (-3.37%)

07:29
09/18/19
09/18
07:29
09/18/19
07:29
Downgrade
Masco rating change  »

Masco downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TNDM

TNDM

07:24
09/18/19
09/18
07:24
09/18/19
07:24
Conference/Events
Tandem Diabetes management to meet with Oppenheimer »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

ADBE

Adobe

$284.59

1.54 (0.54%)

07:23
09/18/19
09/18
07:23
09/18/19
07:23
Recommendations
Adobe analyst commentary  »

Adobe weakness a buying…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 27

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.